Slide 1: Fourth Quarter & Year-end 2024 Operating & Financial Results
Fourth Quarter & Year-end 2024 Operating & Financial Results Conference Call / Webinar March 27th, 2025 4:30 PM Eastern Time NASDAQ :LTRN
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements r
Slide 3: Contents and Speakers
Contents Speakers Panna Sharma David Margrave 01 Introduction CEO and President CFO 02 2024 and Q4 Highlights 03 Financial Highlights 04 Q&A
Slide 4: 4th Quarter 2024 Highlights 1 of 4
2024 ü HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response 4th Quarter rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as Highlights enrollment accelerates in Japan and Taiwan, where 33- 40% of
Slide 5: 4th Quarter 2024 Highlights 2 of 4
2024 ü Successfully dosed multiple patient cohorts in Phase 1A 4th Quarter clinical trials for both LP-184 and LP-284, advancing these synthetic lethal drug candidates toward drug Highlights concentration levels that may show therapeutic efficacy in several cancers of high unmet patient need and wit
Slide 6: 4th Quarter 2024 Highlights 3 of 4
2024 ü Starlight Therapeutics unveiled recurrent GBM trial 4th Quarter design for STAR-001 at SNO 2024, featuring innovative STAR-001+spironolactone combination regimen that Highlights leverages synthetic lethality; assembled world-class Scientific Advisory Board from Johns Hopkins, UCSF, and Memori
Slide 7: 4th Quarter 2024 Highlights 4 of 4
Unveiled innovative AI-powered ADC development 2024 ü module that identified 82 promising targets and 290 target-indication combinations and potentially reducing 4th Quarter development timelines by 30-50% and preclinical costs by up to 60% compared to traditional ADC Highlights development. ü The R
Slide 8: CEO quote on clinical programs and AI in oncology
“With three clinical precision oncology programs actively enrolling patients and critical data milestones on the horizon, we are at the forefront of using AI to transform the cost, pace, and timeline of oncology drug development. Lantern is a leader in the development of tech-bio to deliver the next
Slide 9: Summary Results of Operations
Summary Results of Operations Three Months Ended Year Ended December 31, December 31, 2024 2023 2024 2023 Operating expenses: General and administrative $ 1,626,878 $ 1,304,127 $ 6,090,747 $ 5,983,255 Research and development 4,269,521 3,573,257 16,125,690 11,894,315 Total operating expenses 5,896,3
Slide 10: Balance Sheet Highlights & Summary
Balance Sheet Highlights & Summary December 31, 2024 December 31, 2023 Cash and Marketable Securities $24,013,063 $41,302,672 Prepaid Expenses & Other Current Assets $1,234,566 $2,038,653 Total Assets $25,571,792 $43,647,616 Total Liabilities $4,384,018 $2,739,682 Total Stockholders’ Equity $21,187,
Slide 11: Shares Outstanding
Shares Outstanding December 31, 2024 LANTERN PHARMA INC. (LTRN) Common Shares Outstanding 10,784,725 Warrants 70,000 Options (Employees, Management and Directors) 1,245,694 Fully Diluted Shares Outstanding 12,100,419 NASDAQ: LTRN 10 27
Slide 12: Lantern's diverse & unique AI-driven pipeline of drug programs
Lantern’s diverse & unique AI-driven pipeline of 11 drug programs including RADR® collaborations and Starlight Therapeutics Lantern Pharma (NASDAQ: LTRN) Lead Orphan Rare Fast Indication Discovery Preclinical Phase I Phase II Drug Pediatric Track Candidate Non-Small Cell Lung Cancer LP-300 for Never
Slide 13: Starlight's pipeline is focused on multiple CNS indications
Starlight’s pipeline is focused on multiple CNS indications in both adult and pediatric patients Starlight Therapeutics ADULT CNS CANCERS Orphan Lead Candidate Indication Discovery Preclinical Phase I Phase II Designation RPDD Fast Track First Recurrent Glioblastoma* STAR-001 Newly Diagnosed MGMT Un
Slide 14: Eleven FDA designations strengthen our commercial value
Eleven FDA designations demonstrate our data-driven, AI-enabled approach to transformative drug development & strengthen our commercial value Designation Candidate Indication Date LP-184 Glioblastoma Sep. 2024 Fast Track Designation LP-184 Triple Negative Breast Cancer Dec. 2024 LP-184 Pancreatic Ca
Slide 15: Recent publications highlighting the clinical value of RADR
Recent publications highlighting the clinical value of RADR® in the development of Lantern’s drug candidates PUBLICATION | CHEMBIOCHEM JOURNAL Evaluation of Potency and Specificity of Cryptophycin-Loaded Antibody-Drug Conjugates https://bit.ly/4bZUHua POSTER | SNO ANNUAL MEETING 2024 A Phase 1b Stud
Slide 16: 2025 Objectives
2025 Objectives A Breakthrough Year for Lantern ● Complete Phase 1a clinical trial for LP-184; pursue Phase 1b and investigator led trial(s) T ● Advance enrollment in first-in-human clinical trial for LP-284 in NHL + other cancers O ● Accelerate enrollment of The HarmonicTM Trial in targeted sites i
Slide 17: Connect With Us
NASDAQ: LTRN CONNECT WITH US CONNECT WITH US IR Contact: IR Contact: IR@lanternpharma.com IR@starlighttthera.com 1-972-277-1136 www.lanternpharma.com www.starlightthera.com @LanternPharma @Starlight_Thera linkedin.com/company/lanternpharma linkedin.com/company/starlightthera